Literature DB >> 12373018

Growth and puberty and its management in thalassaemia.

V De Sanctis1.   

Abstract

The purpose of this review is to report the personal experience on growth and pubertal development in a large number of thalassaemic and ex-thalassaemic patients followed at the Pediatric and Adolescent Unit of Ferrara. Secondary amenorrhoea (SA), hypogonadism and short stature are the commonest endocrine and auxological complications. The anterior pituitary gland is particularly sensitive to free radical oxidative stresses and exposure to this. Magnetic resonance imaging (MRI) shows that even a modest amount of iron deposition within the anterior pituitary can interfere with its function. Other possible cause of hypogonadism in beta-thalassaemia major include liver disorders, chronic hypoxia, diabetes mellitus and zinc deficiency. The treatment of pubertal disorders consists of hormone replacement therapy with sex steroids. Successful induction of spermatogenesis and ovulation has been reported after hormonal stimulation with gonadotrophins. Height above the 10th centile was achieved in 50% of males and 64% of females. Eight prepubertal thalassaemic patients, 6 males and 2 females, ranging in age from 8.6 to 11.7 years, were treated with GH. After the first 12 months of GH treatment a significant increase of growth velocity was observed in 6 patients who doubled growth velocity before basal value (4 cm or more above the basal value), 2 patients had a partial response (2-4 cm above the basal value). In the following 3 years all thalassaemic patients had a partial response to the treatment with GH. These data indicate that despite somewhat reduced sensitivity to GH, compared to GH deficiency children, there is evidence indicating that thalassaemic patients may benefit from GH treatment. Sixty-eight thalassaemic patients (30 males and 38 females) who had successfully undergone bone marrow transplantation (BMT) during childhood were studied. Following BMT growth rate decelerated when compared to Tanner and Whitehouse standards. Twenty-nine ex-thalassaemics reached final height. The patterns of growth during puberty was variable in ex-thalassaemic males, while in all but 3 ex-thalassaemic females we observed an improvement in the percentile of standing height. A gonadal dysfunction was found in 68% of ex-thalassaemic patients. Since the quality of life of these patients is an important aim, it is vital to monitor carefully the growth and pubertal development in order to detect abnormalities and to initiate appropriate and early treatment. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12373018     DOI: 10.1159/000064766

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  34 in total

1.  Final height in short polytransfused thalassemia major patients treated with recombinant growth hormone.

Authors:  L Cavallo; V De Sanctis; M Cisternino; M Caruso Nicoletti; M C Galati; A Acquafredda; C Zecchino; M Delvecchio
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

2.  Bone age estimation and prediction of final height in patients with beta-thalassaemia major: a comparison between the two most common methods.

Authors:  Athanasios Christoforidis; Maria Badouraki; George Katzos; Miranda Athanassiou-Metaxa
Journal:  Pediatr Radiol       Date:  2007-10-19

3.  Iron Overload : A Cause of Primary Amenorrhea.

Authors:  Nikita Naredi; Atul Seth; Ajay Sharma
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction.

Authors:  Michael L Nieder; George B McDonald; Aiko Kida; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Michael A Pulsipher; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-01       Impact factor: 5.742

Review 5.  Growth and endocrine function in thalassemia major in childhood and adolescence.

Authors:  M Delvecchio; L Cavallo
Journal:  J Endocrinol Invest       Date:  2010-01       Impact factor: 4.256

Review 6.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

7.  Quantitative T2* magnetic resonance imaging for evaluation of iron deposition in the brain of β-thalassemia patients.

Authors:  S Akhlaghpoor; A Ghahari; A Morteza; O Khalilzadeh; A Shakourirad; M R Alinaghizadeh
Journal:  Clin Neuroradiol       Date:  2011-12-13       Impact factor: 3.649

8.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2020-05-28

Review 9.  Beta-thalassemia.

Authors:  Renzo Galanello; Raffaella Origa
Journal:  Orphanet J Rare Dis       Date:  2010-05-21       Impact factor: 4.123

10.  Osteoporosis syndrome in thalassaemia major: an overview.

Authors:  Meropi Toumba; Nicos Skordis
Journal:  J Osteoporos       Date:  2010-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.